沙库巴曲缬沙坦在心力衰竭儿童中的应用  

Application of sacubitril/valsartanin children with heart failure

作　　者：金伶[1] 杨彤[1] Jin Ling;Yang Tong(Department of Pediatrics,Liuzhou People’s Hospital,Liuzhou 545006,China)

机构地区：[1]广西柳州市人民医院儿科,柳州545006

出　　处：《广西医科大学学报》2020年第9期1744-1747,共4页Journal of Guangxi Medical University

基　　金：广西壮族自治区卫生厅自筹经费科研课题资助项目(No.Z2014414);广西壮族自治区卫生健康委员会自筹经费科研课题(No.Z2020090,No.Z20200078)。

摘　　要：心力衰竭(HF)是儿童急危重症,是由心功能不全、容量或压力超负荷(单独或组合使用)引起,且可引起循环系统、神经激素及分子的异常。现有治疗儿童的HF的药物在临床试验中均未证明有明显疗效。沙库巴曲缬沙坦是新近批准用于成人HF治疗且证实能有效改善HF预后的药物,其可增强内源性利钠肽作用,对神经内分泌及RAAS系统调节起协同作用,作用明显优于单独使用血管紧张素转换酶抑制剂或血管紧张素受体阻滞剂。基于以上优点,其在儿童中的应用将可能有较好的前景。Heart failure(HF)is a pediatric emergency that is caused by cardiac dysfunction,volume or pressure overload(alone or in combination),and can cause circulatory,neurohormonal and molecular abnormalities.None of the drugs available for the treatment of HF in children have demonstrated significant efficacy in clinical trials.Sacubitril/valsartanin is a newly approved drug for the treatment of HF in adults and has been proven to be effective in improving the prognosis of HF.It can enhance the effect of endogenous natriuretic peptides and has a synergistic effect on the regulation of neuroendocrine and RAAS systems,which is significantly better than the use of angiotensin-converting-enzyme inhibitors or angiotensin receptor blockers alone.Based on the above advantages,its application in children will probably have a good prospect.

关 键 词：沙库巴曲缬沙坦 心力衰竭 儿童 

分 类 号：R966[医药卫生—药理学]